Eric Squinto's Colleagues at Gennao Bio
Gary Sender
Independent Director of Public and Private Life Sciences Companies and CEO
Eric Squinto's Contact Details
N/A
New York, New York, United States
Gennao Bio
Eric Squinto's Company Details
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and systemically deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells, including mRNA, synthetic RNA, DNA, si-RNA, ASOs and gene-editing molecules. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.